Worth reading
44Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
141.1
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales62,590¥ millionYear on year +1.9%Progress 24.4%
Operating profit2,099¥ millionYear on year +141.1%Progress 23.3%
Ordinary income2,137¥ millionProgress 26.7%
Net income attributable to owners of the parent1,574¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥28.46
Financial position at period-end
Total assets263,004¥ million
of which net assets 134,644 ¥ millionEquity ratio 51.1%vs. prior year-end -0.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+2,889
Investment-556
Financials-5,953
Net change-3,620
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥44,510 million
Segment revenue
Clinical Testing Products16,38626.2%+16.2%
Testing and related services business39,60363.3%+0.8%
Healthcare-related services business6,60010.5%-17.4%
Segment profit
Clinical Testing Products2,43867.1%+5.6%
Testing and related services business67418.6%
Healthcare-related services business52014.3%-30.8%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥256,000 million (YoY +3.5%)
Operating profit¥9,000 million (YoY +88.3%)
Ordinary income¥8,000 million (YoY +182.3%)
Profit attributable to owners of the parent¥5,000 million (YoY -26.7%)
Annual Dividend Forecast¥125 → ¥125（0.0%）
Factors Behind Changes in Business Performance
The main factor behind the increase in net sales was growth in the clinical diagnostics business, including the foreign exchange impact of the weaker yen. Factors behind the increase in profit included higher net sales, increased contribution margins, including through appropriate pricing in the testing and related services business, improved profitability from fixed-cost reductions, and reduced equity-method investment losses.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 1 / Company name ADx NeuroSciences N.V.
Impairment lossThere were no material impairment losses related to fixed assets during the first quarter of the current fiscal year.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥238 million / Extraordinary loss Loss on Liquidation of Affiliates ¥76 million, Provision for compensation loss ¥70 million, Other ¥27 million
Depreciation and amortization¥4,905 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End57,493,222
Treasury Shares at Period-End2,436,786
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥62,590 million (YoY +1.9%) |
| Operating profit | ¥2,099 million (YoY +141.1%) |
| Ordinary income | ¥2,137 million |
| Profit attributable to owners of the parent | ¥1,574 million |
| Net income per share | ¥28.46 |
| Equity ratio | End of the current fiscal period 51.1 / End of previous period 51.3 |
| Total assets | ¥263,004 million |
| Net assets | ¥134,644 million |
| Cash flows from operating activities | ¥2,889 million |
| Cash flows from investing activities | ¥-556 million |
| Cash flows from financing activities | ¥-5,953 million |
| Cash and cash equivalents at end of period | ¥44,510 million |
| Full-year earnings forecast | Net Sales ¥256,000 million (YoY +3.5%) / Operating profit ¥9,000 million (YoY +88.3%) / Ordinary income ¥8,000 million (YoY +182.3%) / Profit attributable to owners of the parent ¥5,000 million (YoY -26.7%) |
| Annual Dividend Forecast | ¥125 → ¥125（0.0%） |
| Segment revenue | Segment Clinical Testing Products / Net Sales ¥16,386 million / Year on year against the same period last year 16.2, Segment Testing and related services business / Net Sales ¥39,603 million / Year on year against the same period last year 0.8, Segment Healthcare-related services business / Net Sales ¥6,600 million / Year on year against the same period last year -17.4 |
| Segment profit | Segment Clinical Testing Products / Segment profit ¥2,438 million / Year on year against the same period last year 5.6, Segment Testing and related services business / Segment profit ¥674 million / Year on year against the same period last year Not disclosed, Segment Healthcare-related services business / Segment profit ¥520 million / Year on year against the same period last year -30.8 |
| Depreciation and amortization | ¥4,905 million |
| Impairment loss | There were no material impairment losses related to fixed assets during the first quarter of the current fiscal year. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥238 million / Extraordinary loss Loss on Liquidation of Affiliates ¥76 million, Provision for compensation loss ¥70 million, Other ¥27 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 1 / Company name ADx NeuroSciences N.V. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 57,493,222 |
| Treasury Shares at Period-End | 2,436,786 |
| Factors Behind Changes in Business Performance | The main factor behind the increase in net sales was growth in the clinical diagnostics business, including the foreign exchange impact of the weaker yen. Factors behind the increase in profit included higher net sales, increased contribution margins, including through appropriate pricing in the testing and related services business, improved profitability from fixed-cost reductions, and reduced equity-method investment losses. |
Items this document does not state (7)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Growth in the clinical diagnostics business, including the impact of the weaker yen; increased contribution margins, including through appropriate pricing in the testing and related services business; improved profitability from fixed-cost reductions; and reduced equity-method investment losses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.